Quince Therapeutics, Inc. (QNCX) Free cash flow 2018–2025
Quince Therapeutics, Inc. (QNCX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$41.8MFY2025 · since FY2018: -$11.9M → -$41.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$41.8M | -29.9% |
| FY2024 | -$32.2M | -74.3% |
| FY2023 | -$18.5M | +58.2% |
| FY2022 | -$44.2M | +30.0% |
| FY2021 | -$63.1M | -24.1% |
| FY2020 | -$50.9M | -52.6% |
| FY2019 | -$33.3M | -179.9% |
| FY2018 | -$11.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice